for subcutaneous use Initial U.S. Approval: 2016
ixekizumab injection is a humanized interleukin-17A antagonist indicated for the treatment of: • patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. • adults with active psoriatic arthritis. • adults with active ankylosing spondylitis. • adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Facts about ixekizumab injection
MANUFACTURER-Eli Lilly Nederland B.V.
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import ixekizumab injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For ixekizumab injection
Approved accessible "ixekizumab injection"
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. In the United States, ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation. In the European Union it is indicated for the treatment of moderate-to-severe plaque psoriasis and as a second-line therapy for active psoriatic arthritis.
How can 1 go about obtaining ixekizumab injection?
If ixekizumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
TALTZ (ixekizumab) injection, for subcutaneous use Initial U.S. Approval: 2016
- EMA. Human Medicines: Taltz (ixekizumab) cited March 2017
- Summary of Product Characteristics [FDA]: Taltz (ixekizumab) [PDF] Eli Lilly and Co., Dec. 2017.
- Summary of Product Characteristics [TGA]: Taltz (ixekizumab) [PDF] Eli Lilly Australia Pty. Ltd., Apr. 2017.
- Summary of Product Characteristics [EMA]: Taltz (ixekizumab), [PDF] Eli Lilly Nederland B.V., Feb. 2018.
- Instructions for use: Taltz (ixekizumab) prefilled syringe [PDF]
- Drugs@FDA: FDA Approved Drug Products: Taltz (ixekizumab) cited on 16/02/2018
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398